Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Amazon has range of options to invade pharmacy business - Bloomberg

Published 11/07/2017, 01:06 PM
Updated 11/07/2017, 01:06 PM
© Reuters.  Amazon has range of options to invade pharmacy business - Bloomberg
  • Online 8,000-lb. gorilla Amazon (AMZN +0.1%) can make life miserable for prescription drug sellers in a variety of ways according to Bloomberg.
  • At the top of list is leveraging its massive logistics operation to launch a mail-based drug delivery business. Prime membership, where customers pay an annual fee of $99 for unlimited qualified shipments, would be yet another way for Amazon to build customer loyalty among retail prescription drug buyers. Prime Now, with its two-hour delivery, already includes convenience items found in drug stores. It would also be in position to improve the consumer experience using Alexa to shop for medicines online or on mobile devices.
  • Use its buying power to offer customers inexpensive generics, like Walmart (NYSE:WMT), but with the added convenience of online ordering. It could make deals with insurers who do not have a large presence in mail drug delivery such as Humana (HUM +0.3%), Cigna (CI -0.3%) and even UnitedHealth Group (UNH -0.1%).
  • Leverage the physical presence of Whole Foods to set up pharmacies or pick-up points in addition to mail delivery. It could also partner with local independent pharmacies by allowing patients to order medicines online for pick-up at the stores.
  • Buy a drug distributor or pharmacy benefit manager like Express Scripts (ESRX -0.6%) which already operates a large mail-order business. A downside, though, would be the potential exclusion from competitors.
  • Launch a startup. Amazon already owns wholesale distribution licenses in at least 13 states and could build a pharmacy operation from scratch which would enable it to restructure the drug supply chain.
  • Related tickers: (ABC +0.1%)(WBA +3.1%)(CVS +3.3%)(CAH -0.3%)(MCK +1%)(AET -0.4%)
  • Now read: Cardinal Health: Still A Buy After First-Quarter Earnings
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.